Development of a liquid chromatography/tandem-mass spectrometry assay for the simultaneous determination of teneligliptin and its active metabolite teneligliptin sulfoxide in human plasma

Jin Woo Park, Kyoung Ah Kim, Ji Young Park

    Research output: Contribution to journalArticlepeer-review

    1 Citation (Scopus)

    Abstract

    Teneligliptin is a recently developed dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus. To study simultaneous pharmacokinetics of teneligliptin and its major active metabolite, teneligliptin sulfoxide in human plasma, we developed and validated a LC-MS/MS method. The analytes were detected in the positive mode using multiple reaction monitoring (teneligliptin: m/z 427.2→243.1; teneligliptin-d8: m/z 435.2→251.3; teneligliptin sulfoxide: m/z 443.2→68.2). The method demonstrated accuracy, precision, and linearity over the concentration range of 5 to 1000 ng/mL for teneligliptin and 2.5 to 500 ng/mL for teneligliptin sulfoxide. The developed method is the first fully validated method capable of simultaneous determination of teneligliptin and its active metabolite, teneligliptin sulfoxide in plasma. The suitability of the method was successfully demonstrated in terms of quantification of teneligliptin and teneligliptin sulfoxide pharmacokinetics in plasma samples collected from healthy volunteers. The measurement of plasma metabolite/parent ratio of teneligliptin was feasible by this method.

    Original languageEnglish
    Article numbere4721
    JournalBiomedical Chromatography
    Volume34
    Issue number2
    DOIs
    Publication statusPublished - 2020 Feb 1

    Keywords

    • LC-MS/MS
    • teneligliptin
    • teneligliptin sulfoxide

    ASJC Scopus subject areas

    • Analytical Chemistry
    • Biochemistry
    • Molecular Biology
    • Pharmacology
    • Drug Discovery
    • Clinical Biochemistry

    Fingerprint

    Dive into the research topics of 'Development of a liquid chromatography/tandem-mass spectrometry assay for the simultaneous determination of teneligliptin and its active metabolite teneligliptin sulfoxide in human plasma'. Together they form a unique fingerprint.

    Cite this